Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

ARTbio: manufacturing strategy to lead on lead-212 radiotherapies

With $23M seed and tech from alpha-emitter pioneers behind Xofigo, ARTbio to decentralize manufacturing of cancer radiotherapies

By Karen Tkach Tuzman, Director of Biopharma Intelligence
June 22, 2023 10:22 PM UTC

ARTbio is betting cancer radiotherapies based on lead-212 will have an efficacy advantage over more commonly used radioisotopes, and is developing manufacturing strategies to solve the logistical hurdles that are the flip side of its greater potency.

Launched Wednesday with a $23 million seed round, clinical-stage ARTbio Inc. is part of the growing wave of companies developing targeted radiotherapies that emit alpha particles, which deliver more tumor-killing energy over a shorter radius than beta-emitting compounds such as Pluvicto, the prostate cancer radiotherapy from Novartis AG (SIX:NOVN; NYSE:NVS)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article